傳統醫生對大製藥公司的信心粉碎 在葛蘭素的最新騙局後

傳統醫生對大製藥公司的信心粉碎 在葛蘭素的最新騙局後
Conventional doctor's faith in Big Pharma shattered after Glaxo's latest scams
Tuesday, June 29, 2010
by: David Gutierrez, staff writer

(NaturalNews) Writing in Forbes magazine, Yale cardiologist Harlan Krumholz notes that in spite of his desire to believe in the good intentions of the pharmaceutical industry, the actions of companies such as GlaxoSmithKline continue to disappoint him.
（NaturalNews）寫於福布斯雜誌，耶魯大學心髒病專家哈倫克魯姆霍爾茨指出，儘管他渴望相信製藥業的善意，公司如葛蘭素史克的行動繼續令他失望。
"I want to believe in America's pharmaceutical companies," Krumholz wrote on Feb.25. "I want to believe that people in these companies believe that the best strategy for success is to do what is best for patients. I want to believe that they are interested in scientific truth and eager to know of any safety issues and ready to share that information with the public.
“我想要相信美國的製藥公司，”克魯姆霍爾茨在2月25日寫， “我想要相信在這些公司的人們相信，最佳的成功策略就是為病人做最好的。我想要相信他們都對科學真理感興趣，並渴望知道任何的安全議題，並願意與公眾共享資料。
"This week I was disappointed again."
“這一周我再次失望。”
Krumholz was referring to a report, issued by the Senate Finance Committee, concluding that even as Glaxo scientists were voicing warnings about the safety of the blockbuster diabetes drug Avandia, the company was taking aggressive measures to discredit critics who publicly raised similar concerns.
克魯姆霍爾茨是指一個報告，由美國參議院財政委員會發出，結論認為甚至是葛蘭素的科學家們，在出聲警告有關重磅炸彈糖尿病藥物 Avandia的安全，公司卻採取積極措施去詆毀批評者，他們公開提出類似的關注。
"The pages of the Senate report read like a spy novel: Glaxo receiving confidential documents leaked by a sympathetic academic who consulted for the company; the company embarking on a campaign to intimidate critics who warned about potential safety issues with the drug; and executives pulling strings to release data early from a scientific study that was supposedly controlled by an 'independent' committee of researchers," Krumholz said.
“參議院報告的書頁讀來像間諜小說：葛蘭素接收機密文件，被一同情性為公司諮詢的學者洩漏；公司正開展一項活動，去恐嚇批評者他們警告藥物的潛在安全問題;及行政人員扯線去公佈早前來自科學研究的數據，那應是由一'研究員的獨立委員會'控制，“克魯姆霍爾茨說。
The report drew on more than 250,000 internal company documents.
報告借鑒超過 25萬份的公司內部文件。
In his article, Krumholz calls for an end to secrecy and intimidation in pharmaceutical research. He calls for all studies conducted on a drug to be made public for independent review once that drug secures FDA approval. He calls for an end to company interference in the studies they finance, and an end to intimidation of academics who question drugs' safety.

"The free flow of information about the effects of drugs . . . will best serve the public's interest," he concludes.

Sources for this story include: http://www.forbes.com/2010/02/24/diabetes-glaxosmithkline-avandia-business-healthcare-heart-attack.html?boxes=Homepagelighttop

http://www.naturalnews.com/029096_Big_Pharma_scams.html

法國爆出糖尿病劣藥致死醜聞